In recent years, the incidence of lung cancer among middle-aged and elderly people is rapidly increasing, and according to statistics, there are about 500,000 new cases each year in China. Due to the psychological, physiological and metabolic changes of elderly patients, their physical condition is not as good as that of younger patients, and some patients and family members have insufficient knowledge of lung cancer leading to the difficulty of elderly patients to receive active treatment, and often the treatment effect is not as satisfactory. Chen Guo Han, director of thoracic surgery of Oriental Hospital, pointed out that “although the physical condition of elderly people is relatively poor, it does not mean that they can only receive negative treatment. Clinical experience shows that aggressive individualized treatment measures can lead to better outcomes for middle-aged and elderly lung cancer patients.” ”As we entered the twentieth century, the advances in genetics and proteomics, especially the emergence of small molecule complexine kinase inhibitors, pushed molecularly targeted therapy into the history books, and the role of EGFR gene mutations in predicting TKI efficacy opened the door to ‘individualized’ therapy. The treatment paradigm of cancer is shifting from the crude treatment of ‘one size fit all’ to the individualization of ‘Pensonalization of cancer care’. Selecting the right population for the right treatment genetically and proteomically is the true meaning of individualized treatment.” ”Lung cancer is divided into non-small cell lung cancer and small cell lung cancer, of which 80% – 85% are non-small cell lung cancer. lung cancer patients over 65 years of age account for 50% of non-small cell lung cancer patients; about 30% of non-small cell lung cancer and 25% of small cell lung cancer patients are over 70 years of age, known as elderly lung cancer.” Director Chen said, “Since elderly lung cancer patients are older, relatively weak and have various chronic diseases, poorer functions of heart, lung, kidney, liver and bone marrow, there are certain differences in treatment selection and efficacy compared with younger patients. Surgical treatment alone cannot further improve the survival rate nowadays, so a comprehensive treatment model based on surgery should be promoted, especially the treatment of elderly lung cancer should be individualized with ‘different treatment for the same disease’.” ”Older patients with better physical status and early stage of the disease can survive no less than younger patients if they receive aggressive personalized clinical treatment.” Director Chen emphasized, “Therefore, it is hoped that elderly lung cancer patients should believe in science and refrain from seeking medical help when they are sick, believing in biased prescriptions and false propaganda reports. They should use scientific attitude and good attitude to cooperate with doctors’ personalized treatment in order to improve the recovery rate.” Surgery remains the best treatment for elderly people with early stage non-small cell lung cancer if they are in good physical condition. Patients with resectable surgery have significantly longer survival times compared to those who did not undergo surgery. Choosing the appropriate surgical procedure and enhancing perioperative management are key to preventing postoperative complications. Radical radiotherapy should be considered for patients who have not spread metastases and cannot undergo surgery to achieve the best treatment outcome; elderly patients with locally advanced disease should try to receive the correct chemotherapy or radiotherapy. For elderly patients with advanced non-small cell lung cancer, the treatment principle is comprehensive and personalized treatment based on ensuring the quality of survival. Patients at this stage can be considered to receive single agent chemotherapy, non-platinum combination chemotherapy, platinum-containing combination chemotherapy, and targeted therapy. Director Chen said that the main drugs used in clinical practice are the three generations of chemotherapy drugs represented by Kinzel, Tysol or Tysotil, and Noviben. The adverse effects of the third generation chemotherapy drugs have been greatly reduced compared with the first two generations, and most elderly patients are treated with these drugs as monotherapy, so the toxic side effects are mild. The widespread use of new generation antiemetics has significantly reduced nausea and vomiting reactions in a portion of patients receiving combination chemotherapy regimens containing cisplatin or carboplatin, and has made chemotherapy for elderly lung cancer patients no longer a deterrent treatment; but a treatment option that significantly improves the quality of life and prolongs survival. Targeted drug therapy, represented by ERSA and Troche, has been clearly proven to have good efficacy for those who failed first-line treatment, especially effective for Oriental population, non-smokers and women, adenocarcinoma and alveolar cancer, making a breakthrough in the treatment of advanced lung cancer. They have become the standard second- and third-line treatment regimen with ease of administration, relatively mild adverse effects and clear efficacy. Finally, Director Chen emphasized, “In conclusion, the treatment of lung cancer must be based on the actual situation of patients, tumor stage, pathological staging, etc. In particular, patients, family members and doctors should be reminded that in the treatment of locally advanced non-small cell lung cancer, it is incorrect to treat patients with potential cure with palliative chemotherapy that is completely incurable; in addition, over-treatment, especially excessive chemotherapy that seriously affects the survival of lung cancer patients and even endangers their lives, resulting in inappropriate treatment that leaves both people and money empty, should also be avoided. “